Table 2 outlines the number of participants in each group, their demographics, and the corresponding mean CSF concentrations of the AD biomarkers. Seven participants had no recorded measurement of total tau. The names, abbreviations, and functional pathway classifications for these markers are provided in Supplementary Table 1. This evidence concerns the gene MAPT and Alzheimer disease.